Mechanism of Action
Melanocortin Receptor Agonism
Activation of central melanocortin receptors (MC3R/MC4R) modulating sexual function, appetite, and skin pigmentation.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Compounds
2
Total studies
115
Human studies
24
FDA approved
1
Overview
Melanocortin agonists activate one or more of the melanocortin receptor subtypes (MC1R-MC5R). MC1R in skin modulates melanin production; MC3R/MC4R in the CNS modulate sexual arousal, appetite, and energy balance. Selective or non-selective targeting produces distinct clinical profiles — from sexual dysfunction treatment to skin tanning.
The melanocortin system controls pigmentation (MC1R), steroidogenesis (MC2R), and appetite and sexual function (MC3R/MC4R). Drug development has focused primarily on MC4R for weight management and sexual function, with bremelanotide (PT-141) gaining FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. The pharmacology of the MC4R pathway intersects with genetic obesity syndromes — setmelanotide is FDA approved for MC4R pathway deficiencies (POMC, LEPR, PCSK1).
Receptor & signaling detail
Melanocortin receptors are class A GPCRs. MC4R is expressed in hypothalamic nuclei (paraventricular, arcuate), brainstem, and spinal cord, governing appetite, autonomic tone, and sexual behavior. MC1R is restricted to melanocytes and some immune cells. All five receptors couple primarily to Gαs → cAMP.
How it works
- 1Binds to melanocortin receptors (GPCRs).
- 2Activates Gαs → cAMP → PKA signaling.
- 3MC4R activation in hypothalamus drives sexual arousal.
- 4MC1R activation in melanocytes increases eumelanin synthesis.
- 5MC3R/MC4R activation can suppress appetite.
Downstream clinical effects
- Increased sexual desire and arousal (MC4R)
- Skin darkening / tanning (MC1R)
- Reduced appetite (MC4R)
- Changes in pigmented lesions (melanotan class)
Documented clinical implications
- Increased sexual desire and arousal (MC4R activation, FDA-approved)
- Reduced appetite in MC4R-deficient genetic obesity (setmelanotide, FDA-approved)
- Skin pigmentation increase (MC1R — melanotan II use)
- Potential cardiovascular and autonomic effects
Limitations & mechanism-driven side effects
- Bremelanotide is limited to on-demand use; long-term chronic dosing is not the approved pattern
- Melanotan II has significant safety concerns (cardiovascular, dermatological, new nevus formation)
- Nausea is a common side effect across the class
- Pigmentation and cardiovascular effects can be off-target
Discovery & development
Alpha-MSH, the endogenous melanocortin, was characterized in the 1950s. Melanotan II was synthesized in the 1980s for sunless tanning; bremelanotide was derived from melanotan II specifically for sexual function after observations during dermatology trials.
Peptides using this mechanism
An FDA-approved melanocortin receptor agonist used for hypoactive sexual desire disorder in premenopausal women.
A melanocortin receptor agonist that stimulates melanin production (tanning) and has sexual function effects. Significant safety concerns.
Evidence status
Bremelanotide (PT-141) is FDA approved for HSDD. Melanotan II is used only in research / unregulated contexts.
Frequently asked questions
Is bremelanotide safe for long-term use?
Bremelanotide (PT-141) is approved for on-demand use, not continuous dosing. Long-term safety data for chronic daily administration is limited.
Why does melanotan II cause mole changes?
MC1R activation stimulates melanocyte activity system-wide, including in existing nevi. New nevus formation and changes in existing moles have been reported with melanotan II use.
Does bremelanotide work for men?
Bremelanotide is FDA approved for premenopausal women with hypoactive sexual desire disorder. Trials in men have shown effects on erectile function, but it is not FDA approved for male indications.
Can melanocortin agonism cause weight loss?
Yes — in MC4R-pathway genetic obesity, setmelanotide (a MC4R agonist) produces substantial weight loss. In common obesity, MC4R agonism has shown less robust effects.
Relevant best-of guides
Related articles
Peptides for Women: Safety, Benefits, and What’s Different
Deep Dive · 14 min
PT-141 vs Melanotan II: Melanocortin Agonists and Sexual Function
Comparison · 8 min
Melanotan II vs PT-141: Melanocortin Peptides Compared
Comparison · 8 min
Best Peptides for Women: Safety & Evidence Guide 2026
Guide · 8 min
How Long Do Peptides Take to Work? A Compound-by-Compound Timeline
Learn · 8 min